Medtronic (NYSE:MDT) Given New $78.00 Price Target at Deutsche Bank Aktiengesellschaft

Medtronic (NYSE:MDT) had its price target dropped by equities research analysts at Deutsche Bank Aktiengesellschaft from $100.00 to $78.00 in a report issued on Thursday,MarketScreener reports. The firm currently has a “hold” rating on the medical technology company’s stock. Deutsche Bank Aktiengesellschaft’s price target suggests a potential downside of 5.19% from the stock’s current price.

Several other research analysts have also recently weighed in on MDT. Jefferies Financial Group reiterated a “hold” rating and issued a $88.00 price target on shares of Medtronic in a report on Thursday. Leerink Partners cut their price objective on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating on the stock in a research report on Thursday. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Medtronic in a research note on Thursday. Piper Sandler lowered their target price on Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a report on Wednesday, April 1st. Finally, Evercore set a $106.00 price target on Medtronic and gave the company an “outperform” rating in a research note on Thursday, April 9th. Sixteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.45.

Medtronic Stock Up 5.5%

Shares of NYSE MDT traded up $4.32 during mid-day trading on Thursday, reaching $82.27. 2,865,182 shares of the company’s stock were exchanged, compared to its average volume of 9,074,854. Medtronic has a twelve month low of $73.31 and a twelve month high of $106.33. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $105.63 billion, a price-to-earnings ratio of 22.92, a PEG ratio of 1.76 and a beta of 0.58. The business has a fifty day simple moving average of $81.67 and a 200 day simple moving average of $92.21.

Medtronic (NYSE:MDT) last posted its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. The business had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.Medtronic’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the prior year, the business earned $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities analysts expect that Medtronic will post 5.54 EPS for the current fiscal year.

Institutional Trading of Medtronic

Hedge funds have recently modified their holdings of the stock. Lodestone Wealth Management LLC acquired a new position in Medtronic in the 4th quarter valued at about $27,000. Anfield Capital Management LLC lifted its position in Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the last quarter. Monetary Solutions Ltd acquired a new stake in Medtronic during the fourth quarter worth approximately $27,000. Board of the Pension Protection Fund bought a new stake in shares of Medtronic during the fourth quarter worth approximately $29,000. Finally, GoalVest Advisory LLC bought a new stake in shares of Medtronic during the fourth quarter worth approximately $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported fiscal Q4 revenue of $9.81 billion and adjusted EPS of $1.55, both ahead of estimates, which reinforced the recent stock move higher.
• Positive Sentiment: Cardiac Ablation Solutions revenue surged 78% globally, helping offset margin pressure and signaling strong demand in a key growth franchise.
• Positive Sentiment: Management lifted its quarterly dividend to $0.72 per share and kept FY2027 growth targets intact, supporting the case for continued operational momentum.
• Positive Sentiment: Medtronic also announced new strategic investments and FDA-related submissions to expand its Hugo robotic-assisted surgery platform, which could add future growth opportunities. Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery system
• Neutral Sentiment: Several analysts lowered price targets this morning, but most kept constructive ratings such as overweight, outperform, or buy, suggesting valuation concerns rather than a changed bullish thesis.
• Neutral Sentiment: Wells Fargo cut its target to $102 from $114 and Leerink cut to $104 from $117, while Robert W. Baird reduced its target to $85 and kept a neutral rating.
• Negative Sentiment: Medtronic’s FY2027 EPS guidance of $5.90 to $6.00 came in below the consensus estimate, which may temper some of the post-earnings enthusiasm.
• Negative Sentiment: Margins remain a focus as the company flagged tariff and cost headwinds, which could pressure profitability even as sales improve.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).